Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease

被引:48
|
作者
Zhou, Ming [1 ]
Zhang, Wangming [1 ]
Chang, Jingyu [2 ]
Wang, Jun [1 ]
Zheng, Weixin [1 ]
Yang, Yong [1 ]
Wen, Peng [1 ]
Li, Min [1 ]
Xiao, Hu [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China
[2] Neurosci Res Inst North Carolina, Winston Salem, NC USA
基金
中国国家自然科学基金;
关键词
Parkinson's disease; Gait; CatWalk; 6-Hydroxydopamine; Neurochemical correlation; STIMULATION; LOCOMOTION; INITIATION; DISORDERS; MOVEMENT; 6-OHDA; SPEED;
D O I
10.1016/j.neulet.2014.10.032
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gait deficits are important clinical symptoms of Parkinson's disease (PD) but are rarely studied. In this study we made three different rat PD models by administration of 6-hydroxydopamine into caudate putamen (CPU), medial forebrain bundle (MFB) and substantia nigra compact (SNC). We evaluated the gait changes in these models by using a computer-assisted CatWalk system. Correlations of gait parameters with tyrosine hydroxylase protein levels in the CPU and SNC were also investigated. The gait readouts were significantly impaired in both the MFB and SNC groups. However, the MFB group showed a more pronounced impairment than the SNC group. In contrast, only mild and incomplete gait impairment occurred in the CPU group. In addition, some gait parameters demonstrated close correlation with the protein levels of TH. This paper suggests that the 6-hydroxydopamine-induced MFB model is more propitious to study gait dysfunction than the other two models and the CatWalk system can provide reliable and objective criteria to stratify gait changes arising from 6-hydroxydopamine lesioned rats. These findings may hold promise in the study of PD disease progression and new therapeutic methods. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [21] Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease
    Sadeghian, M.
    Mullali, G.
    Pocock, J. M.
    Piers, T.
    Roach, A.
    Smith, K. J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (05) : 423 - 435
  • [22] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson’s Disease
    Sang J. Na
    Anthony G. DiLella
    Edward V. Lis
    Keith Jones
    David M. Levine
    David J. Stone
    J. F. Hess
    Neurochemical Research, 2010, 35 : 761 - 772
  • [23] Neuroprotection of edaravone in a 6-hydroxydopamine model of Parkinson's disease
    Li, G.
    Tian, J.
    MOVEMENT DISORDERS, 2006, 21 : S344 - S345
  • [24] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson's Disease
    Na, Sang J.
    DiLella, Anthony G.
    Lis, Edward V.
    Jones, Keith
    Levine, David M.
    Stone, David J.
    Hess, J. F.
    NEUROCHEMICAL RESEARCH, 2010, 35 (05) : 761 - 772
  • [25] Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: Implications for treating Parkinson's disease?
    Wang, S
    Hu, LF
    Yang, Y
    Ding, JH
    Hu, G
    NEUROPHARMACOLOGY, 2005, 48 (07) : 984 - 992
  • [26] Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson's disease models
    Lan-Xiang Liu
    Dan Du
    Zhan-Qiu Wang
    Yuan Fang
    Tao Zheng
    Yan-Chao Dong
    Qing-Lei Shi
    Min Zhao
    Fang Xiao
    Juan Du
    Neural Regeneration Research, 2018, 13 (07) : 1276 - 1280
  • [27] Neuroprotective and Antiapoptotic Potential of Trigonelline in a Striatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
    M. Mirzaie
    M. Khalili
    Z. Kiasalari
    M. Roghani
    Neurophysiology, 2016, 48 : 176 - 183
  • [28] Transcriptome profiling of five brain regions in a 6-hydroxydopamine rat model of Parkinson's disease
    Lyu, Ying
    Huang, Yiying
    Shi, Guiying
    Lei, Xuepei
    Li, Keya
    Zhou, Ran
    Bai, Lin
    Qin, Chuan
    CNS NEUROSCIENCE & THERAPEUTICS, 2021, 27 (11) : 1289 - 1299
  • [29] Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease
    Maia, Serge
    Arlicot, Nicolas
    Vierron, Emilie
    Bodard, Sylvie
    Vergote, Jackie
    Guilloteau, Denis
    Chalon, Sylvie
    SYNAPSE, 2012, 66 (07) : 573 - 583
  • [30] Depletion of brain glutathione potentiates the effect of 6-hydroxydopamine in a rat model of Parkinson's disease
    García, JC
    Remires, D
    Leiva, A
    González, R
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2000, 14 (03) : 147 - 153